Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer. by Saunders, M. I. et al.
BrTbsh Journal of Cancer (1998) 78410). 1323-1 328
© 1998 Cancer Research Campaign
Experience with dose escalation using CHARTWEL
(continuous hyperfractionated accelerated radiotherapy
weekend less) in non-small-cell lung cancer
Ml Saunders', A Rojas2, BE Lyn', K Pigott', M Powell', K Goodchild', PJ Hoskin', H Phillips' and N Verma
Marie Curie Research Wing. Mount Vemon Hospital Northwood. Middlesex HA6 2RN. UK: 2'Gray Laboratory Cancer Research Trust. PO Box 100. Northwood.
Middlesex HA6 2JR. UK
Summary Results from the multicentre randomized trial of CHART (continuous, hyperfractionated, accelerated radiotherapy) in non-small-
cell lung cancer (NSCLC) showed a significant increase in survival (P = 0.004) compared with conventional radiotherapy and a therapeutic
benefit relative to late radiation-induced morbidity. However, 60% of patients died because of failure to control locoregional disease. These
findings have stimulated interest in assessing the feasibility of dose escalation using a modified CHART schedule. Acute and late morbidity
with a CHARTWEL (CHART WeekEnd Less) schedule of 54 Gy in 16 days was compared with that observed with 60 Gy in 18 days in patients
with locally advanced NSCLC. The incidence and severity of dysphagia and of analgesia were scored using a semiquantitative clinical scale.
Late radiation-induced morbidity, namely pulmonary. spinal cord and oesophageal strictures, were monitored using clinical and/or radiological
criteria. Acute dysphagia and the analgesia required to control the symptoms were more severe and lasted longer in patients treated with
CHARTWEL 60 Gy (P< 0.02). However, at 12 weeks, oesophagitis was similar to that seen with 54 Gy and did not lead to consequential
damage. Early radiation pneumonitis was not increased but, after 6 months, there was a higher incidence of mild pulmonary toxicity compared
with CHARTWEL 54 Gy. No cases of radiation myelitis, oesophageal strictures or of grade 2 or 3 lung morbidity have been encountered.
CHARTWEL 60 Gy resulted in an enhancement of oesophagitis and grade 1 lung toxicity compared with CHARTWEL 54 Gy. These were of
no clinical significance. but may be important if CHARTWEL is used with concomitant chemotherapy. These results provide a basis for further
dose escalation or the introduction of concurrent chemotherapy.
Keywords: continuous, hyperfractionated, accelerated radiotherapy; continuous. hyperfractionated, accelerated radiotherapy weekend
less; dose escalation: acute morbidity: late morbidity: non-small-cell lung cancer
Non-small-cell lung cancer (NSCLC) is one of the most common
causes ofcancer-related deaths in the developed w-orld. Surgery is
the treatment ofchoice but it is curative onlv in earls sta2e disease
which. unfortunatelx. constitutes the minoritv of cases at the time
of diagnosis. Patients with more adsvanced tumours apparently
localized to the chest max be treated by radical radiotherapy. The
outcome is. hosever. poor with 1-. 2- and 5-sear survival rates of
40%-. 15%e and 5c% respectively. and a median sursisal time of 10
months after a consentional 6- to 7-seek course of radiotherapy
(Perez et al. 1987). Results from a recent randomized radiotherapy
trial in NSCLC show-ed that uncontrolled disease at the primary
site was the principal cause of death in 60% of patients and was
present at death in almost 90%7- of them (Saunders et al. 1997:
unpublished data). confirming, earlier post-mortem data (Saunders
et al. 1984). This suggests that much could be gained by
improving, the manaaement of locoregional disease. Over the last
ts o decades. attempts to improve local tumour control in NSCLC
have included. among others. the use ofoxxcen-mimetic radiosen-
sitizers (Saunders et al. 1982: Simpson et al. 1989). hi2h-LET
radiation (Lindslev et al. 1996) and adjuxant chemotherapy
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(Buccheri and Ferrtrno. 1996). all of which ha-e made little. if
any. impact on patient survisal.
Although the solume doubling time of NSCLC is slow, these
tumours has e the potential to undergo ses eral cell doublings
during the course of consentional radiotherapy. In a recent study
of in visvo BUdR labelling, the median T of 28 tumour biopsies
Vwas 7 days. but in some specimens it wvas as little as 1.6 days
(Wilson. 1991). Therefore. it wsould appear that locoregional
response in NSCLC could be improsed by the use of treatment
acceleration. CHART (continuous hyperfractionated accelerated
radiotherapy ) is the most accelerated form ofcuratise radiotherapy
and aims to reduce tumour clonogYen proliferation and. by using a
dose per fraction <2 Gs. also to reduce the risk of late complica-
tions. After a successful pilot study of CHART at Mount Vernon
hospital. Northsood. UK. in NSCLC (Saunders and Dische.
1990). a multicentre randomized controlled trial w-as undertak-en
betw.een 1990 and 1995. in which CHART was compared sith
consventional radiotherapy in 563 patients. A recent update of the
data has shown a 24% reduction in the relative risk of death w-ith
CHART which translates into an absolute improvement at 1 y-ear
of 8%- (63%- vs 55%-) and at 2 -ears of 9%- (29%- vs 20%): the
differences are statistically significant (P = 0.004). There has been
no indication of an increase in late morbiditv and. therefore. a
significant therapeutic gain is achiesed with this schedule
(Saunders et al. 1997).
These results have stimulated interest in dose escalation w-ith
CHART. To asoid shortening the interfraction inten-al and maintain
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Table 1 Scoring cnteriaa for early and late morbidity
Scores
Morbidity 0 1 2 3 4
Acute
Dysphagia None Discomfort on Soft diet Fluids only Severe difficutty
swallowing required with fluids
Analgesia None Surface Non-narcotic Narcotic
medicine only medicines medicines
Chronic
Dysphagia None Due to tumour Due to X-ray therapy Cause unknown
(stricture)
Lung: None Symptoms Symptoms Symptoms
clinical not interfering requiring hospitalized!
with lifestyle treatment house bound
Lung: None Slight Moderate Severe
radiological
Cord None LHermittes Incomplete Complete
paraplegia paraplegia
aScoring systems from Dische et al (1989).
the therapeutic benefit of a loxw dose per fraction on late morbiditx.
the increase in total dose can only be achiexed bv increasing, the
overall treatment time. To make such a regime more easily
applicable in other centres. it w-as proposed to modify the
CHART protocol into a CHART WeekEnd Less regime. hence
CHARTWTL. This paperreports normal tissue responses in patients
with NSCLC treated with CHARTWEL schedules usina doses of
54-60 GC in an oxerall time of 16-18 days. As x-ould be expected
w-ith radical accelerated reggimes. acute reactions are dose-limitinn.
in particular oesophageal mucositis for this site. The extent ofacute
morbiditx was monitored by scoring the incidence and sexeritv of
dysphagia and the degree of analgesia required by each patient
during and afterradiotherapy for aperiod ofup to 8 weeks. The inci-
dence and sexeritx of late morbiditv was monitored throughout the
duration of the study: in particular dysphagia radiation-induced
lung damaae and radiation mxelitis. Local tumour control and
survix al were also assessed.
MATERIALS AND METHODS
Approxal for this study was gixen by the local Ethics Committee
and written informed consent Awas obtained from each patient.
From July 1990 to September 1996. 64 patients with histologi-
cally proven NSCLC confined to the thorax were entered into the
study. Fortv-nine were men and 15 %vere women x-ith an age ranre
of 45-80 years (median 66 years). Thirty-fixe patients. who were
considered unsuitable for the randomized CHART trial. were
included betmeen July 1990 and April 1995. After the conclusion
of that trial. all patients. except two. eligible for radical radio-
therapy were treated with the 60 Gy in 18 days CHARTWEL
protocol. and this comprised the last 29 patients. Those two
patients were deemed to be at greater risk of sexere radiation-
induced pneumonitis because of prior lung pathology and were
treated x-ith the 54Gy schedule. All patients were inxestigated
with a chest radiograph. bronchoscopy. computerized tomography
(CT) scan of the chest and histology or brush cytologx. The pres-
ence of liver metastases was assessed biochemically and by CT
or ultrasound. Further investigations to exclude metastases were
carried out onlv ifclinicallv indicated.
Table 2 Details of patients with NSCLC treated with CHARTWEL
CHARTWEL 54 Gy CHARTWEL 60 Gy
Number of patients 17 30
Men:Women 14:3 19:11
Age (years)
Range 48-76 45-79
Mean 64 63
Median 63 66
Stage
3 1
11 _ 8
IIIA 10 19
IIIB 4 2
The treatment was dixided into two phases. In all patients.
except nine. the phase I v-olume included the mediastinum and
primary7 tumour x ith a 1-cm margin. These patients had peripheral
tumours and were irradiated with localized fields. which excluded
the mediastinum. The mediastinum Aas defined as extending from
the suprasternal notch to 3 cm belowx the carina. The ipsilateral
hilar nodes and paratracheal nodes were included but the contralat-
eral hilum excluded. The phase H volume included the tumour and
known nodal inxolvement with a 1-cm margin. Three or fourfields
were used throuahout treatment and correction x as made for
transmission through the lung. Radiation doses were prescribed to
the intersection point of the beams (Department of Health. 1978).
The large volume received a dose of37.5 Gy and the small volume
16.5 Gy escalating, to 22.5 Gy. Dose to the spinal cord dose wxas
limited to a maximum of 44 Gy and that to the lunas. outside the
planned target volume. to 20 Gy.
Radiotherapy wxas gixen on a 6/10-MeV linear accelerator. In
the four different CHARTWEL protocols. the same indixvidual
intersection dose (ID) per fraction as in CHART of 1.5 Gy was
given three times per day. using a 6-h interfraction interx al.
Monday-Friday. The total dose of 54 Gx in 36 fractions was
reached in 16 davs. Total doses of 57. 58.5 and 60 Gxwere
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Figure 1 (A) Mean dysphagia scores averaged over a period of 8 weeks
from start of radiotherapy for patients treated with CHARTWEL 54 Gy in 16
days (*; n = 17) or treated with CHARTWEL 60 Gy in 18 days (A; n = 22).
Error bars are + 1 s.e.m. (B) Time during which non-narcotic medication
(score 2 in Table 1) was administered to patients treated with either
CHARTWEL 54 Gy (0; n = 17) or CHARTWEL 60 Gy (A; n = 22). Solid
symbols represent the mean (+ 1 s.e.m.) for each group
achieved by increasing the number of fractions to 38, 39 and 40
respectively. Seventeen patients received 54 Gy, seven were
treated to 57 Gy in 17 days, ten patients a dose of 58.5 Gy also in
17 days, whereas 30 patients received 60 Gy over 18 days. Two
patients, both in the 60 Gy arm, were excluded from the analysis.
In one of these patients, radiotherapy was interrupted after 28 Gy
because of brain metastases and the other patient died less than 2
weeks after the end oftreatment as a result of the primary tumour.
The patients were seen weekly for 6 weeks from the start of treat-
ment, then at 8 weeks and subsequently every 3 months up to 2
years, then twice a year up to 5 years and annually thereafter. Table
I summarizes the criteria used for quantitating early and late
morbidity in oesophagus, lung and spinal cord. These scoring
systems were developed in our department and have been used
successfully in previous studies, including the CHART random-
ized trial (Dische et al, 1989).
During treatment and until the acute reaction had settled, the
severity of dysphagia and the medicines prescribed to ameliorate
the symptoms were recorded. An arbitrary scale from 0 to 4 for
dysphagia and from 0 to 3 for analgesia was used. The scores were
recorded on weeks 1, 2, 3, 4, 5, 6 and 8 during or after radio-
therapy. For the calculation of dysphagia and analgesia, the data
from the 17 patients treated with 54 Gy, seven with 57 Gy, seven
of the ten treated with 58.5 Gy and 22 of the 28 patients treated
with 60 Gy were used. These were eliminated from the analysis of
acute morbidity because the irradiation fields excluded the medi-
astinum. As there was no indication that acute or late reactions in
the 57 and 58.5 Gy were higher than those seen with 54 Gy,
comparisons in the paper are presented for CHARTWEL 54 Gy
relative to CHARTWEL 60 Gy. Table 2 summarizes the staging
and demographic details of these two groups.
For each patient, the individual weekly scores for dysphagia
were plotted and an area under the curve (AUC), reflecting
severity and duration of the acute reaction, was calculated by the
trapezoid rule using a graphics package (Origin, Microcal). For
clarity of presentation, a mean score as a function of time after
treatment was obtained for each dose group. This procedure,
however, has no strict statistical validity because the scale is non-
parametric. A median value of dysphagia was calculated for each
treatment and compared with the median score for analgesia given
to patients during the same follow-up period. Table 3 summarizes
median values of AUCs and analgesia in patients treated with
CHARTWEL 54 or 60 Gy. To enable a statistical comparison
between groups, for each patient the duration ofdysphagia or anal-
gesia was calculated at three cut-off points (Table 3). The signifi-
cance in differences between treatments was estimated by carrying
out Student's t-test using a standard statistical analysis computer
package (JMP, SAS Institute).
At all subsequent follow-up attendances, radiation side-effects
were monitored. Quantitation of late radiation-induced morbidity
was made using the scoring criteria shown in Table 1. At each
follow-up, a chest radiograph was performed and a CT scan at 3-
monthly intervals. Morbidity was analysed and statistical compar-
isons were made by computing actuarial disease-free intervals
using the product-limit (Kaplan-Meier) method. Late oesophageal
damage was taken as that occurring after the acute reactions had
settled (i.e. after 3 months). Findings from clinical and radiolog-
ical examinations were used to distinguish between the dysphagia
due to tumour and that due to radiotherapy. Lung damage was
diagnosed both by clinical and radiological examination. Acute
pneumonitis was taken as the syndrome occurring during the first
6 months from first treatment, and late pulmonary toxicity as that
evolving after this time. Two separate actuarial analyses were
made: one which included patients with scores 1-3 and another
which only considered scores 2 or 3 as positive events for either
pneumonitis or late lung dysfunction (Table 1).
Local tumour control was defined as being achieved when there
was either complete disappearance ofall abnormalities in the chest
radiograph or CT scan, or when any residual abnormality observed
at 6 months remained stable for a further 6 months or more.
Patients who did not achieve local tumour control were defined as
never being disease-free and were considered an event at time 0.
Overall survival was taken as the time from first treatment to
death; patients still alive were censored at the time last seen. The
response to treatment was assessed by calculating local tumour
control and overall survival using the product-limit (Kaplan-
Meier) method.
RESULTS
Figure 1A shows mean dysphagia scores over the first 8 weeks
after the start of radiotherapy in patients with carcinoma of the
bronchus treated with either 54 Gy in 16 days or 60 Gy in 18 days.
The reactions peaked on weeks 3 and 4 and, in general, the mean
scores for dysphagia in patients treated with the higher dose were
greater than that of patients receiving 54 Gy. This resulted in a
higher median value for AUC for CHARTWEL 60 Gy and in a
small, but significant, prolongation in the duration of mild and
British JoumalofCancer(1998) 78(10), 1323-1328
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Figure 2 Actuarial analysis of early or late radiation-induced lung damage in patients treated with CHARTWEL 54 Gy (solid lines) or CHARTWEL 60 Gy
(dashed lines) using either the clinical (A-C) or radiological (D) scoring systems summarized in Table 1. (A and B) Incidence of pneumonitis-free survival
occurring in the first 6 months after radiotherapy considering patients with scores 1-3 (A) or scores 2-3 (B) as responders. (C) Incidence of late mild pulmonary
complications when all levels of lung dysfunction are taken as a positive event was higher for CHARTWEL 60 Gy (P = 0.03; log rank). (D) Percentage of
patients free of radiological abnormalities in the irradiated volume assessed by either chest radiograph or CT scans (scores 2 or 3)
intermediate dysphagia. However, there was no difference in the
duration ofgrade 3 symptoms (Table 3). The severity ofdysphagia
can be monitored also by the degree of analgesia required to
control symptoms. In this study, there was a strong correlation
between the intensity and duration of dysphagia (i.e. the area
under the curve) and the mean score of analgesia calculated for
each patient (r = 0.8). On the whole, a less severe form and/or a
shorter duration of analgesia was administered to patients treated
with 54 Gy (Figure IB), and there was a significant increase in the
time during which either surface medication or non-narcotic anal-
gesia were administered after CHARTWEL 60 Gy (P<0.01).
Even though actuarial analysis of dysphagia at 12 weeks after
radiotherapy indicated a 12% and 5% incidence of radiation-
induced oesophageal damage in patients treated with
CHARTWEL 54 and 60 Gy respectively, this difference was not
statistically significant (data not shown). There was no consequen-
tial necrosis in either ofthe two groups.
The incidence of patients free of clinical symptoms of early
pneumonitis and late lung morbidity are shown in Figure 2 using
either the clinical (Figure 2A-C) or the radiological criteria
(Figure 2D). Two separate analyses are presented: one for patients
exhibiting any degree of dysfunction (scores 1-3 in Table 1) and
another for patients presenting only the more severe symptoms
(scores 2 or 3). At 6 months, just under 60% of patients treated
with 54 Gy were pneumonitis-free compared with 69% in the
60 Gy arm (all scores). When the higher scores were used as
cut-offpoints, 82% and 88% ofpatients were free ofclinical signs
of pulmonary complications. The difference in the incidence of
acute radiation pneumonitis between the two schedules was not
significant. There was no clinical evidence of moderate or severe
late lung dysfunction, i.e. none ofthe patients presented a score of
2 or 3 (data not shown). However, ifpatients with mild symptoms
not interfering with life style were considered as responders (i.e.
score 1), there was a significant increase in the incidence ofgrade
1 pulmonary toxicity with CHARTWEL 60 Gy. Two years after
radiotherapy, over 80% of these patients showed some degree of
lung impairment, compared with a less than 10% incidence in
those treated with CHARTWEL 54 Gy (P = 0.03; Figure 2C).
When the radiological assessment of lung damage was used for
quantitating radiation-induced injury and considering only those
patients with a score of 2 or 3 as responders, almost all presented
evidence of damage in the irradiated volume, as would be
expected (Figure 2D). In either of the two schedules, there have
been no cases ofL'Hermittes, radiation myelitis or ofoesophageal
strictures.
DISCUSSION
These data show that when the total radiation dose in aCHARTWEL
schedule to NSCL carcinomas was increased from 54 Gy in 16 days
to 60 Gy in 18 days, the acute oesophageal reactions were signifi-
cantly enhanced. Although hardly any difference was observed in
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Table 3 Median values for severity and duration of dysphagia (AUC) and median severity scores for analgesia. Number of patients and mean time at a score
of 1. 2 or 3
End point CHARTWEL 54 Gy CHARTWEL 60 Gy P-value
(n = 17) (n = 22)
Dysphagia
Median AUCa 5 7.8
No. patients withscores > 1 (%O) 17 (100) 22 (100)
Mean duration t 1 s.e.m. (weeks) 3.59 0.32 4.73 -0.31 0.016
No. patients with scores > 2 (O0) 12 (71) 17 (77)
Mean duration + 1 s.e.m. (weeks) 1.29 - 0.29 2.50 - 0.38 0.02
No. patients withscores > 3 (00) 2 (12) 4 (18)
Mean duration - 1 s.e.m. (weeks) 0.11 - 0.08 0.23 -0.11 0.5
Analgesia
Median 0.57 1.0
No. patients with scores > 1 (ow) 16 (94) 22 (100)
Mean duration - 1 s.e.m. (weeks) 2.76 - 0.32 4.82 t 0.26 c0.0001
No. patients wth scores > 2 (00) 9 (53) 17 (77)
Mean duration - 1 s.e.m. (weeks) 1.12 - 0.32 2.64 _0.45 0.01
No. patients with scores = 3 (°%) 1 (6) 1 (5)
Mean duration - 1 s.e.m. (weeks) 0.12 - 0.12 0.05 - 0.05 0.5
aArea under the curve.
the time to and in the magnitude ofpeak dysphagia. at all follow-up
times the reactions were higher in the CHARTWEL 60 Gy group.
This resulted in a 45%7 increase in the area under the curve for
dysphagia with this schedule (Fiaure lA). The data also indicate that
with both reaimes oesophaggeal mucositis had not altogether settled 8
weeks after radiotherapy. In spite ofthis. there has been no evidence
ofconsequential necrosis in either ofthese tuo groups. The type and
duration of analgesia after CHARTWEL 60 Gs was also greater.
with a more than tx-ofold increase in the time during which non-
narcotic medication w-as administered (Figure lB and Table 3). It is
perhaps surprising that both ofthe assays used forquantitating early
morbidity in this fast-proliferating tissue were sensitive enough to
detect just oxer a 10%7c increase in radiation dose. The enhancement
ofoesophagitis wxith the higherdose schedule was not due to alonger
length of the oesophagus being encompassed. either in the large or
reduced treatment volume. but w%as due to an increase in radiation
dose to it (data not shown). It should be emphasized that the increase
in acute but transitory oesophageal mucositis was of no clinical
concem because healing occurred in all cases and there was no
evidence of long-term complications. By contrast. the Radiation
Therapy Oncology Group (RTOG) study of dose escalation from
60Gv to 69.5 Gy with hNperfractionation showed no increase in
acute morbidity. possibly because the overall treatment time was
sufficientlv long to allow for full compensatory proliferation in the
mucosa (Cox et al. 1990). Care must be taken. however. ifconcomi-
tant chemotherapy is to be given with CHARTWEL because the
extra amount of cell kill may precipitate more severe early and/or
late morbidity. as has been reported by others (Ball et al. 1995).
Neither moderate nor severe late complications. in particular
spinal cord. have arisen inany ofthe patients. Although an enhance-
ment ofthe acute oesophageal reaction wxas seen with CHARTWEL
60 Gy. the incidence ofstrictures due to radiation wxas nil. Likewise.
the incidence and severity of pneumonitis xxas similar in both
groups. Furthermore. none of the patients showed clinical evidence
ofmoderate or sexere late lunc dysfunction. Nevertheless. 6 months
or more after radiotherapy. there xas a large increase in the inci-
dence of mild pulmonary symptoms in the 60 Gy schedule. The
areas of the anterior fields in both phases were not greater in this
schedule and it is. therefore. unlikely that larger xvolumes of lung
were irradiated. However. we cannot totally exclude the possibility
of factors other than dose escalation contributing to this effect. The
increase in pulmonary dysfunction was due to an excess ofgrade 1
morbiditv and. as such. does not interfere with the patients' lifestyle.
but should be bome in mind when considerinc adjuvant treatment
wvith CHARTWEL 60 Gv. Like us. the dose-escalation RTOG trial
showed no enhancement of sexere late normal tissue complications.
but aboxve 69.5 Gv survival was not improxed and life-threateninr
morbidity may have contributed to this result (Cox et al. 1990).
In changing, from CHART. xhich is administered in 12 daxs. to
CHARTWEL 60 Gy given in 18 davs. there has been an increase in
the oxerall treatment time of 6 days. At I year. just oxer 40% of
tumours in patients in the 54 Gy arm were in clinical and radio-
loaical remission. compared with 45%t/ of those treated with 60 Gv
(data not showxn). The incidence fell to 30%- in the low--dose
schedule. but remained unchanged in the latter regime. In the first
18 months after radiotherapy. there xxas no difference in oxerall
survival betxxeen the tw-o groups. None ofthese comparisons were.
however. statisticallv different from one another. In NSCLC. Cox et
al (1993) and Koukourakis et al (1996) haxe shown time to be an
important factor in treatment outcome. These studies haxe used
treatment times longer than 3 weeks after which time tumour
repopulation may commence. as has been indicated for squamous
cell carcinomas of the head and the neck (Withers et al. 1988:
Slexvin et al. 1992). For a very short schedule such as CHART. an
extension from 12 days to a CHARTWEL regime in 18 daysswould
be expected to haxe less influence on repopulation. Indeed. if this
small study is compared with results from the randomized or pilot
CHART trial. there has been no indication of a reduction in local
tumour control (Saunders and Dische. 1990: Saunders et al. 1997).
In conclusion. patients treated w-ith CHARTWEL 60 Gy haxe
experienced an increase both in acute oesophageal morbidity and
in grade 1 late lung dysfunction compared with patients treated
with 54 Gv. However. this enhancement of normal tissue reactions
has not led to complications requiring a different or more intensive
type of medical management. nor has it affected the quality of
life of patients. Aiming still to improve locoregional control in
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NSCLC. we now plan to evaluate the CHARTWEL 60 Gy regime
with concurrent chemotherapy in locally advanced disease.
However, the difficulty will lie in identifying an effective druc
combination that does not compromise the therapeutic benefit of
CHART and CHARTWEL regimes.
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